Xiaoyun Li, Andrew Lewandowski, Huafeng Zhou, A. Lawrence Gould, Kuenhi Tsai Estimation Comparison of Pharmacokinetic Models Using MONOLIX, PKBUGS, and NONMEM
|
Aristides Dokoumetzidis, Richard Magin, Panos Macheras Fractional kinetics in multi-compartmental systems
|
J. G. Coen van Hasselt (1,2), Ron J. Keizer (1,2), M. van Benten (3), Alwin D. R. Huitema (1,2) Implementation of an affordable computing cluster for pharmacometric analysis
|
Ron J Keizer, Robert S Jansen, Hilde Rosing, Jos H Beijnen, Jan HM Schellens, Alwin DR Huitema Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses
|
Ivelina Gueorguieva1 and Malcolm Rowland2 Is pharmacokinetic variability in microdosing trials comparable to variability following therapeutic doses?
|
Michael Heathman (1), Donald Jennings (1), and Bernett Lee (2) Interactive Simulation and Visualization of Drug/Disease Models
|
Leonid Gibiansky, Ekaterina Gibiansky Target-Mediated Drug Disposition: New Derivation of the Michaelis-Menten Model, and Why It Is Often Sufficient for Description of Drugs with TMDD
|
M. Petrone (1), S. Beato (2), R. Gomeni (1), F. Gray (3) Integrated approach to overcome a food effect in clinical studies: an example of how in vitro, in vivo and simulation tools can help in determining an appropriate strategy
|
Justin Wilkins & Michael Looby A comparison of two model-based approaches to investigating covariate effects on the dose-exposure relationship in a Phase III context
|
O. Lillin-de Vries, R. de Greef, T. Kerbusch Population PK-PD modeling of thorough QT/QTc data allows for mechanistic understanding of observed QTc effects
|
W. Knebel*(1), T. Bergsma (1), C. Dagdigian (2), J. Hane (1), M. R. Gastonguay (1) A Strategy for Efficient Implementation of NONMEM 7 and the Intel Fortran Compiler in a Distributed Computing Environment
|
Meg Bennetts Simulation Methodology for Quantitative Study Decision Making in a Dose Response Setting
|
F. Ezzet Analysis of Adverse Events using Literature Data: a Simulation Study
|
F. Ezzet (1), J. Ribbing (2) Bronchial Allergen Challenge in Asthma: A Model for Inhaled Corticosteroids (ICS) and Montelukast using Literature Summary Data
|
F. Ezzet (1), K. Prins (2), M. Boucher (3) Modeling Adverse Event rates of Opioids for the Treatment of Osteoarthritis Pain using Literature Data
|
Tobias Sing, Martin Fink, Michael Looby An R package for industrializing concentration-QT analysis
|
A. Dubois (1), S. Gsteiger (2), E. Pigeolet (2) and F. Mentré (1) Model-based bioequivalence analysis of pharmacokinetic crossover trials compared to standard non-compartmental analysis
|
Brigitte D. Lacroix(1,2), Maria Laura Sargentini-Maier(2), Mats O. Karlsson(1) and Lena E. Friberg(1) Simultaneous modeling of the three ACR improvement thresholds – 20, 50 and 70% - in rheumatoid arthritis patients treated with certolizumab pegol
|
Metelkin E., Smirnov S., Gizzatkulov N., Demin O. Circulator Is a New Technique for Systems Pharmacology
|
J. Bertrand (1), C.M. Laffont (2), E. Comets (1), M. Chenel (3), F. Mentré (1) Genetic effect on a complex parent-metabolite joint PK model developed with NONMEM and MONOLIX
|
C. Navarro(1), C. Fernandez-Teruel(2), I. Gonzalez-Alvarez(3), A. Garcia-Arieta(4), M. Bermejo(3), VG Casabó(1) Bioequivalence trials simulation to select the best analyte for drugs with two metabolic pathways
|
C. Diack (3), O. Ackaert (3), B. Ploeger (3), P. van der Graaf (1), R. Gurrell (2), M. Ivarsson (2), D. Fairman (1) A true Markov model for sleep disturbance
|
C. Steven Ernest II and Andrew C. Hooker Predictor Identification in Time-to-Event Analyses
|
M Boucher Imputation of missing variance data comparing Bayesian and Classical non- linear mixed effect modelling to enable a precision weighted meta-analysis.
|
Dickinson, GL Evaluation of a Method to Better Predict Human Absorption from Non-Clinical Data; Comparison of an in silico approach with population modelling of in vivo data
|
Henry Pertinez, Leon Aarons Bayesian POP-PK analysis of exposure data from a Phase IIb clinical trial
|
Colomban O. (1)(2), Naudet B. (3), Maucort-Boulch D. (3), Roy P. (3), Girard P. (2) Toxicogenomic dose-response models for DNA chips data from rats treated by flutamide
|
Paolo Denti (1), Helen McIlleron (1) Modelling pre-dose concentrations in steady-state data. The importance of accounting for between-occasion variability and poor adherence.
|
Tarjinder Sahota (1), Meindert Danhof (1), Oscar Della-Pasqua (1,2) Model-based safety thresholds for discrete adverse events
|
P. Westwood, P. Collier, S. Yakkundi A Pharmacokinetic Study of Ranitidine in a Paediatric Population
|
Tarjinder Sahota (1), Nuria Buil (2), Katsutoshi Hara (2), Oscar Della Pasqua (1,2) The Chicken and the Egg in Interoccasion Variability
|
Thaddeus H. Grasela* (1), Jill Fiedler-Kelly (1), Darcy J. Hitchcock (1), Elizabeth A. Ludwig (1), Julie A. Passarell (1) Forensic Pharmacometrics: Part 1 - Data Assembly
|
Thaddeus H. Grasela* (1), Jill Fiedler-Kelly (1), Elizabeth A. Ludwig (1), Julie A. Passarell (1), Darcy J. Hitchcock (1) Forensic Pharmacometrics: Part 2 - Deliverables for Regulatory Submission
|
I. Locatelli, M. Bogataj, A. Mrhar, I. Grabnar The Development of a Link Model Consisting of in vitro Drug Release and Tablets Gastric Emptying Time: Application to Diclofenac Enteric Coated Tablets
|
Leonid Gibiansky, Ekaterina Gibiansky TMDD Model for Drugs that Bind Soluble and Membrane-Bound Targets: Can Quasi-Steady-State Approximation Estimate Unobservable Membrane-Bound Target Occupancy?
|